WO2006013103A3 - Induzierbare genexpression - Google Patents

Induzierbare genexpression Download PDF

Info

Publication number
WO2006013103A3
WO2006013103A3 PCT/EP2005/008427 EP2005008427W WO2006013103A3 WO 2006013103 A3 WO2006013103 A3 WO 2006013103A3 EP 2005008427 W EP2005008427 W EP 2005008427W WO 2006013103 A3 WO2006013103 A3 WO 2006013103A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
gene expression
inducible gene
transgene
expression
Prior art date
Application number
PCT/EP2005/008427
Other languages
English (en)
French (fr)
Other versions
WO2006013103A2 (de
Inventor
Frank Notka
Ralf Wagner
Diana Hammer
Original Assignee
Geneart Gmbh
Frank Notka
Ralf Wagner
Diana Hammer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geneart Gmbh, Frank Notka, Ralf Wagner, Diana Hammer filed Critical Geneart Gmbh
Priority to JP2007523036A priority Critical patent/JP2008507290A/ja
Priority to EP05768069A priority patent/EP1774008A2/de
Priority to CA002575480A priority patent/CA2575480A1/en
Priority to US11/658,206 priority patent/US8691533B2/en
Publication of WO2006013103A2 publication Critical patent/WO2006013103A2/de
Publication of WO2006013103A3 publication Critical patent/WO2006013103A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Die vorliegende Erfindung betrifft Vektorkonstrukte für eine HIV-spezifische Gentherapie. Die Expression der Transgene ist an eine Infektion der Zelle mit HIV gekoppelt, indem die Transkription des Transgens durch eine von HIV abgeleitete Transkriptionskontrollregion kontrolliert wird. Das Transgen wird außerdem durch Modifikation der Nukleotidsequenz in der RNA­Stabilität und Expressionseffizienz verbessert.
PCT/EP2005/008427 2004-08-03 2005-08-03 Induzierbare genexpression WO2006013103A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2007523036A JP2008507290A (ja) 2004-08-03 2005-08-03 誘導性遺伝子発現
EP05768069A EP1774008A2 (de) 2004-08-03 2005-08-03 Induzierbare genexpression
CA002575480A CA2575480A1 (en) 2004-08-03 2005-08-03 Inducible gene expression
US11/658,206 US8691533B2 (en) 2004-08-03 2005-08-03 Inducible gene expression

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004037611A DE102004037611B4 (de) 2004-08-03 2004-08-03 Induzierbare Genexpression
DE102004037611.5 2004-08-03

Publications (2)

Publication Number Publication Date
WO2006013103A2 WO2006013103A2 (de) 2006-02-09
WO2006013103A3 true WO2006013103A3 (de) 2006-06-01

Family

ID=35787483

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/008427 WO2006013103A2 (de) 2004-08-03 2005-08-03 Induzierbare genexpression

Country Status (7)

Country Link
US (1) US8691533B2 (de)
EP (1) EP1774008A2 (de)
JP (1) JP2008507290A (de)
CN (1) CN101035899B (de)
CA (1) CA2575480A1 (de)
DE (1) DE102004037611B4 (de)
WO (1) WO2006013103A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4550115B2 (ja) * 2004-08-03 2010-09-22 ジーンアート・アクチエンゲゼルシャフト ＣｐＧ含量を変化させることにより遺伝子発現を調整する方法
KR101449587B1 (ko) * 2006-09-14 2014-10-10 메드제닉스 메디칼 이스라엘 리미티드 장기 지속형 약물 제형
US8454948B2 (en) 2006-09-14 2013-06-04 Medgenics Medical Israel Ltd. Long lasting drug formulations
CN102108362B (zh) * 2009-12-24 2014-06-25 上海市农业科学院 一种优化的三苯甲烷还原酶基因及其表达和应用
CN103260649A (zh) 2010-06-15 2013-08-21 迈德詹尼克斯医疗以色列有限公司 长效药物制剂
WO2012103496A2 (en) * 2011-01-28 2012-08-02 Medimmune, Llc Expression of soluble viral fusion glycoproteins in mammalian cells
US20130303726A1 (en) 2012-04-17 2013-11-14 Chiesi Farmaceutici S.P.A. Method for the preparation of surfactant peptides
JP6824594B2 (ja) 2014-09-11 2021-02-03 Jnc株式会社 合成遺伝子の設計方法
PE20231949A1 (es) * 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
JP7517704B2 (ja) 2019-06-21 2024-07-17 国立大学法人大阪大学 外来遺伝子を安定的に保持する人工組換えｒｎａウイルスの作製方法
CA3186830A1 (en) * 2020-07-21 2022-01-27 Zhongdong SHI Composition and method for treating eye diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998034640A2 (en) * 1997-02-07 1998-08-13 Merck & Co., Inc. Synthetic hiv gag genes
WO2000039304A2 (en) * 1998-12-31 2000-07-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP1156112A1 (de) * 2000-05-18 2001-11-21 Geneart GmbH Synthetische Gene für gagpol und deren Verwendungen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0917585B1 (de) * 1996-07-22 2007-04-11 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Vektoren zur inhibierung von viralem und tumorwachstum
DE10053781B4 (de) * 2000-10-30 2008-07-03 Geneart Ag Kernexportreportersystem
DE10260805A1 (de) 2002-12-23 2004-07-22 Geneart Gmbh Verfahren und Vorrichtung zum Optimieren einer Nucleotidsequenz zur Expression eines Proteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998034640A2 (en) * 1997-02-07 1998-08-13 Merck & Co., Inc. Synthetic hiv gag genes
WO2000039304A2 (en) * 1998-12-31 2000-07-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP1156112A1 (de) * 2000-05-18 2001-11-21 Geneart GmbH Synthetische Gene für gagpol und deren Verwendungen

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CARA A ET AL: "INHIBITION OF HIV-1 REPLICATION BY COMBINED EXPRESSION OF GAG DOMINANT NEGATIVE MUTANT AND A HUMAN RIBONUCLEASE IN A TIGHTLY CONTROLLED HIV-1 INDUCIBLE VECTOR", GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 5, no. 1, 1998, pages 65 - 75, XP000914885, ISSN: 0969-7128 *
FURUTA R A ET AL: "HIV-1 capsid mutants inhibit the replication of wild-type virus at both early and late infection phases", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 415, 1997, pages 231 - 234, XP002159812, ISSN: 0014-5793 *
WAGNER R ET AL: "REV-INDEPENDENT EXPRESSION OF SYNTHETIC GAG-POL GENES OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 AND SIMIAN IMMUNODEFICIENCY VIRUS: IMPLICATIONS FOR THE SAFETY OF LENTIVIRAL VECTORS", HUMAN GENE THERAPY, vol. 11, no. 17, 20 November 2000 (2000-11-20), pages 2403 - 2413, XP000974656, ISSN: 1043-0342 *

Also Published As

Publication number Publication date
JP2008507290A (ja) 2008-03-13
DE102004037611A1 (de) 2006-03-16
DE102004037611B4 (de) 2013-10-02
EP1774008A2 (de) 2007-04-18
US8691533B2 (en) 2014-04-08
CA2575480A1 (en) 2006-02-09
CN101035899B (zh) 2012-05-02
WO2006013103A2 (de) 2006-02-09
CN101035899A (zh) 2007-09-12
US20110033429A1 (en) 2011-02-10

Similar Documents

Publication Publication Date Title
WO2006013103A3 (de) Induzierbare genexpression
WO2002000894A3 (en) Gene silencing vector
WO2005014806A3 (en) Conserved hbv and hcv sequences useful for gene silencing
WO2005098004A3 (en) Inducible boost of integrated satellite rna viruses
WO2005077117A3 (en) Transgenic corn seed with enhanced amino acid content
EP2270161A3 (de) Expressionskonstrukte mit mehreren RNA-Polymerase-III-Promotern
WO2006069064A3 (en) Conserved hbv and hcv sequences useful for gene silencing
WO2006053683A3 (en) Gene silencing using sense dna and antisense rna hybrid constructs coupled to peptides facilitating the uptake into cells
WO2006012221A3 (en) Target cell-specific short interfering rna and methods of use thereof
WO2008133643A8 (en) Plant micrornas and methods of use thereof
EP2281897A3 (de) Onkolytische Mutante des Herpes Simplex Virus
WO2004065613A3 (en) Inducible small interfering rna (sirna) expression constructs for targeted gene silencing
WO2007130604A3 (en) Anti-tumor activity of an oncolytic adenovirus-delivered oncogene sirna
WO2006012393A3 (en) Addition of transgenes into adenoviral vectors
IL185147A0 (en) Replication-deficient rna viruses as vaccines
WO2010090857A3 (en) Methods for amplifying hepatitis c virus nucleic acids
WO2004047764A3 (en) Modulation of hiv replication by rna interference
EP1841871A4 (de) Neuer l-lysin-induzierbarer promotor
WO2003093485A3 (en) Optimization of transgene expression in mammalian cells
WO2008133137A1 (ja) 遺伝子治療のためのベクター
WO2004035782A3 (en) Sirna mediated gene silencing in transgenic animals
WO2007046787A3 (en) Methods of reducing repeat-induced silencing of transgene expression and improved fluorescent biosensors
EP1728859A4 (de) Zur beschleunigung der genexpressionbei einer mässig niedrigen temperatur fähige sequenz
EP2121928B1 (de) Verwendung von doppelstrang-rna-haarnadel-duplexen beim gen-silencing
WO2007115385A3 (en) Transfer plasmidic vector and recombinant canarypox virus

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2005768069

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11658206

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2007523036

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2575480

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 2005768069

Country of ref document: EP